25 May 2013
Keywords: biogen, idec, agrees, 200m, deal, ucb, oral
Article | 09 October 2006
Belgium's UCB and US drugmaker Biogen Idec have entered a global collaboration to jointly develop and commercialize CDP323 for the
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 October 2006
24 May 2013
© 2013 thepharmaletter.com